Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.77 -2.92 (-5.15%)
Streaming Delayed Price Updated: 12:35 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
From Genentech
Via Business Wire
News headline image
NovoCure Q4 EPS Misses, Revenue Matches ↗
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
News headline image
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
News headline image
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
From Genentech
Via Business Wire
News headline image
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
From Genentech
Via Business Wire
News headline image
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. 
Via Benzinga
News headline image
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years ↗
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
Via Benzinga
News headline image
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants ↗
Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits. 
Via Benzinga
Topics Cannabis
News headline image
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint ↗
The company is also facing off with biosimilars for standard Eylea and competition with Roche. 
Via Investor's Business Daily
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
News headline image
Roche CEO Reassures No Job Cuts Despite Challenges: Report ↗
Roche Holding AG reportedly says no layoffs planned. CEO Schinecker provides pipeline updates including potential anti-obesity drug by 2029. 
Via Benzinga
Topics Workforce
News headline image
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease ↗
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
News headline image
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits ↗
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
News headline image
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains. 
Via Benzinga
News headline image
New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
From Genentech
Via Business Wire
News headline image
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
From Genentech
Via Business Wire
News headline image
The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:AMZN),(NASDAQ:MDAI),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
News headline image
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
Las Vegas, NV – December 4, 2024 – Avant Technologies, Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
NVIDIA Invested in These 2 AI Stocks, Should You?
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? ↗
Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.